Earnings Call Summary | Zimmer Biomet Holdings(ZBH.US) Q1 2024 Earnings Conference
Earnings Call Summary | Zimmer Biomet Holdings(ZBH.US) Q1 2024 Earnings Conference
The following is a summary of the Zimmer Biomet Holdings, Inc. (ZBH) Q1 2024 Earnings Call Transcript:
以下是Zimmer Biomet Holdings, Inc.（ZBH）2024年第一季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
Zimmer Biomet reported a Q1 2024 revenue growth of 4.4%, exceeding company expectations due to strong markets and effective execution.
Q1 2024 net sales were $1.889 billion, a reported increase of 3.2% or 4.4% excluding foreign currency's impact.
Gross margin was increased due to sales growth, accelerated savings from the restructuring program and a lower share count.
Despite a 200 basis point increase in the effective tax rate, Zimmer expanded its adjusted margin and grew its adjusted earnings.
Operating cash inflows and free cash inflow during Q1 2024 were reported as $228 million and $91 million, respectively.
The company's GAAP diluted earnings per share stood at $0.84 while adjusted diluted earnings per share were reported at $1.94.
Zimmer Biomet报告称，由于强劲的市场和有效的执行，2024年第一季度收入增长4.4％，超出了公司的预期。
2024年第一季度的净销售额为18.89亿美元，据报告增长3.2％，增长4.4％，不包括外币的影响。
毛利率的增加是由于销售增长、重组计划带来的节约加速以及股票数量的减少。
尽管有效税率提高了200个基点，但Zimmer还是扩大了调整后的利润率并增加了调整后的收益。
据报告，2024年第一季度的运营现金流入和自由现金流入分别为2.28亿美元和9,100万美元。
该公司的GAAP摊薄后每股收益为0.84美元，而调整后的摊薄后每股收益为1.94美元。
Business Progress:
业务进展：
Zimmer experienced high patient demand, driven by demographic shifts affecting their end markets.
Globally, ROSA technology and Persona Knee products' adoption was a primary driver of results.
Revenue growth is expected to accelerate in H2 2024 due to new product releases including Persona OsseoTi, HAMMR surgical impactor, and ROSA Shoulder.
Zimmer is entering the direct anterior hip category with their triple taper hip stem, Z1, increasing competition in that market.
Strategic priorities focusing on people and culture, operational excellence, and diverse innovation were upheld for long-term success.
The company improved their inventory management programs significantly and promised a notable improvement in Days on Hand (DOH) in 2024.
Zimmer aims for 5% to 6% revenue growth and EPS growth between $8 to $8.15 in 2024, with expected free cash flow generation between $1.0 to $1.1 billion.
The company leans towards smaller, accretive tuck-in acquisitions of up to $2 billion, expecting these to be EPS neutral within two years and aims to regain their leading position in Hip surgery with their latest product innovations.
Zimmer Biomet persisted in investing in areas of potential high-growth such as robotic penetration and cementless adoptions, aiming for 60% penetration.
受影响终端市场的人口结构变化的推动，Zimmer 的患者需求居高不下。
在全球范围内，ROSA技术和Persona Knee产品的采用是业绩的主要驱动力。
由于包括Persona OsseoTi、HAMMR手术冲击器和ROSA Shoulder在内的新产品的发布，预计收入将在2024年下半年加速。
Zimmer凭借其三锥度髋关节杆Z1进入直前髋关节类别，这加剧了该市场的竞争。
坚持以人员和文化、卓越运营和多元创新为重点的战略重点，以取得长期成功。
该公司显著改善了库存管理计划，并承诺在2024年显著改善Days on Hand（DOH）。
齐默的目标是在2024年实现5％至6％的收入增长，每股收益增长8至8.15美元，预计产生的自由现金流在10亿至11亿美元之间。
该公司倾向于进行规模较小、增值高达20亿美元的收购，预计这些收购将在两年内实现每股收益中和，并计划通过最新的产品创新重新获得其在髋关节外科领域的领先地位。
Zimmer Biomet坚持投资于潜在的高增长领域，例如机器人渗透率和无水泥采用率，目标是达到60％的渗透率。
More details: Zimmer Biomet Holdings IR
更多详情： Zimmer Biomet 控股投资者关系
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。